Please note that the details of this Challenge are no longer open. This challenge is awarded and is no longer accepting new submissions. You can:
Challenge <p>PET Imaging Probes for Visualization and Quantification of Oligonucleotide Exposure</p>

PET Imaging Probes for Visualization and Quantification of Oligonucleotide Exposure

STATUS: Awarded
Active Solvers: 174
Posted: Dec 12 2017
Challenge ID: 9934086
 
Team Project Rooms are available on this Challenge. Team Share Challenge Share
Abstract

Use of oligonucleotide based drugs for treatment of brain disorders is an evolving field, but also generates some new challenges relating to delivery and monitoring of brain exposure in patients. For small molecules, positron emission tomography (PET) has been an instrumental technique for non-invasively determining brain exposure, however for oligonucleotides, PET imaging technology is not well developed. Therefore, the Seeker desires a method to improve the visualization of oligonucleotides by PET imaging for accurate quantification of oligonucleotide exposure.

This Theoretical Challenge requires only a written proposal.

 

Overview

The use of PET tracers in the development of small molecules has proven invaluable for establishing the relationship between the administered dose and the concentration of the drug at the site of action. For oligonucleotides, PET tools are not as developed and rely on direct labeling of the compound with radioligands, which have various limitations. To avoid the complications associated with the injection of radiolabeled oligonucleotides, the Seeker desires a method where oligonucleotide concentrations can be probed at various time points using a PET probe that binds selectively to the oligonucleotide. Selectivity can be achieved by covalently linking the oligonucleotide to a conjugate that is then recognized by the PET probe. For illustration this could be biotin (probe) binding to avidin (conjugate). The Seeker desires a probe-conjugate pair that has the properties required for clinical PET studies of oligonucleotide exposure.

This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker.

To receive an award, the Solvers will not have to transfer their exclusive IP rights to the Seeker. Instead, Solvers will grant to the Seeker a non-exclusive license to practice their solutions. 

Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on February 10, 2018. 

Late submissions will not be considered.

What is InnoCentive?
InnoCentive is the global innovation marketplace where creative minds solve some of the world's most important problems for cash awards up to $1 million. Commercial, governmental and humanitarian organizations engage with InnoCentive to solve problems that can impact humankind in areas ranging from the environment to medical advancements.

What is a Theoretical-Licensing Challenge?

An InnoCentive Theoretical Challenge builds upon an idea but is not yet a proof of concept. A solution to a Theoretical Challenge will solidify the Solver's concept with detailed descriptions, specifications and requirements necessary to bringing a good idea closer to becoming an actual product or service.

This Challenge is a Theoretical-Licensing Challenge, meaning that the Seeker is requesting non-exclusive rights to use the winning solution. By contrast, Theoretical-IP Transfer means that Solvers must relinquish all rights to the Intellectual Property (IP) for which they are awarded. For these forms of a Theoretical Challenge, Solvers that do not win retain the rights to their solution after the evaluation period is complete. The Seeker retains no rights to any IP not awarded.

Share This Challenge
InnoCentive Trust Partners